Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Post by Bakatareon Jan 02, 2015 3:41pm
183 Views
Post# 23280795

Ebola fighters

Ebola fighters

Time magazine named the "Ebola fighters" as their 2014 'Person of Year' Dec. 10, highlighting among others Dr. Thomas Geisbert, a virologist formerly with the U.S. Army Medical Research Institute of Infectious Diseases who conducted some of the first trials of the drug TKM-Ebola.

In an interview for the magazine, Geisbert talked about his experiences during the 1990s and early 2000s at USAMRIID, which is a biosafety level 4 lab located on Fort Detrick in Frederick, Maryland. At the time, as they studied Ebola virus and potential vaccine candidates, others were not as interested. Geisbert described how excited he was that USAMRIID's scientific contributions led to drugs that supported the current outbreak response.

"In this Ebola outbreak, we know at least four to five people got the TKM drug, and all have survived. But we don't want to say the drug was the reason they survived. While we hope they helped in patients, we can't say for sure because the patients got so many other things. There are so many confounding variables, so how can you say any one thing made the difference? But it's a great feeling knowing I was involved in the development of something that hopefully saved somebody. And if it saved one person, it matters," said Geisbert, in his Time magazine interview.

Although Geisbert has since moved on to the University of Texas Medical Branch at Galveston, other researchers at USAMRIID have continued the fight against Ebola. In fact, the efforts to develop diagnostic capabilities, in addition to prevention and treatment countermeasures have increased dramatically for USAMRIID and the other units within the U.S. Army Medical Research and Materiel Command.

Bullboard Posts